Bioconjugate Chemistry · 2012 · 65 citations · 33 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DeliverySupramolecular ChemistryLipid Bilayer StructureLipid BilayersLipid ChemistryLipid StructureNanocarriers For TherapeuticsNanomedicineAntineoplastic Drug TherapyDegradation KineticsLipid VesiclesLiposomal NanocarriersLiposome Delivery SystemsLiposomesMetal-organic Supramolecular Assemblies
A novel ruthenium complex, linked to a cholesterol-containing nucleolipid (named ToThyCholRu), stabilized by lipid aggregates for antineoplastic therapy is presented. In order to retard the degradation kinetics typically observed for several ruthenium-based antineoplastic agents, ToThyCholRu is incorporated into a liposome bilayer formed by POPC. The resulting nanoaggregates contain up to 15% in moles of the ruthenium complex, and are shown to be stable for several weeks. The liposomes host the ruthenium-nucleolipid complex with the metal ion surrounded by POPC lipid headgroups and the steroid moiety inserted in the more external acyl chain region. These ruthenium-containing liposomes are more effective in inhibiting the growth of cancer cells than a model NAMI-A-like ruthenium complex, prepared for a direct evaluation of their anti-proliferative activity. These results introduce new perspectives in the design of innovative transition-metal-based supramolecular systems for anticancer drug vectorization.
33
A M Krieg, John L. Tonkinson, Sara Matson et al. · Proceedings of the National Academy of Sciences · 1993 · 204 citations
Enzo Alessio, Gabriele Balducci, Mario Calligaris et al. · Inorganic Chemistry · 1991 · 193 citations
Transition metal complexes as potential therapeutic agents
Shazia Rafique, M. Idrees, Anwar Nasim et al. · Biotechnology and Molecular Biology Reviews · 2010 · 179 citations · Full text